Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer

PURPOSE: SCLC is an aggressive malignancy affecting nearly 30,000 people annually in the United States. We have previously identified elevated PARP1 levels in SCLC and demonstrated in vitro sensitivity to the PARP inhibitors AZD 2281 and AG014699. Here, we evaluate activity of a novel, potent PARP i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Cardnell, Robert, J, Feng, Ying, Diao, Lixia, Fan, You-Hong, Masrorpour, Fatemah, Wang, Jing, Shen, Yuqiao, Mills, Gordon, B, Minna, John, D, Heymach, John, V, Byers, Lauren, A
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3882158/
https://ncbi.nlm.nih.gov/pubmed/24077350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-13-1975
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares